期刊文献+

胰腺癌的早期诊断 被引量:1

暂未订购
导出
摘要 所谓早期胰腺癌是指肿瘤直径≤2cm,且局限于胰实质内,无胰腺外浸润及淋巴结转移,早期胰腺癌相当于TNM分期T1期。
出处 《岭南现代临床外科》 2009年第5期323-326,共4页 Lingnan Modern Clinics in Surgery
  • 相关文献

参考文献7

二级参考文献22

  • 1朱庆云,屠振兴,李兆申,满晓华.Mesothelin在胰腺癌组织的表达及其临床意义[J].胰腺病学,2005,5(1):17-20. 被引量:8
  • 2Argani P,Iacobuzio-Donahue C,Ryu B,et al. Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE). Clin Cancer Res,2001,:3862-3868.
  • 3Chang K,Pastan I. Molecular cloning of mesothelin,a differentiation antigen present on mesothelium,mesotheliomas,and ovarian cancers. Proc Natl Acad Sci USA,1996,3: 136-140.
  • 4Bera TK,Pastan I. Mesothelin is not required for normal mouse development or reproduction. Mol Cell Biol,2000,0:2902-2906.
  • 5Chang K,Pastan I,Willingham MC. Isolation and characterization of a monoclonal antibody,K1,reactive with ovarian cancers and normal mesothelium. Int J Cancer,1992,50:373-381.
  • 6Chowdhury PS,Viner JL,Beers R,et al. Isolation of a high-affinity stable single-chain Fv specific for mesothelin from DNA-immunized mice by phage display and construction of a recombinant immunotoxin with anti-tumor activity. Proc Natl Acad Sci USA,1998,95:669-674.
  • 7Hassan R,Viner JL,Wang QC,et al. Anti-tumor activity of K1-LysPE38QQR,an immunotoxin targeting mesothelin,a cell-surface antigen overexpressed in ovarian cancer and malignant mesothelioma. J Immunother,2000,23:473-479.
  • 8Kojima T,Oh-eda M,Hattori K,et al. Molecular cloning and expression of megakaryocyte potentiating factor cDNA. J Biol Chem,1995,270:21984-21990.
  • 9Scholler N,Fu N,Yang Y,et al. Soluble member(s) of the mesothelin/megakaryocyte potentiating factor family are detectable in sera from patients with ovarian carcinoma. Proc Natl Acad Sci USA,1999,96:11531-11536.
  • 10Maguchi H. The roles of endoscopic uhrasonography in the diagnosis of pancreatic tumors. J Hepatobiliary Pancreat Surg, 2004,11:1-3.

共引文献44

同被引文献24

  • 1胡先贵.努力提高胰腺癌术后长期生存率[J].第二军医大学学报,2005,26(8):842-844. 被引量:7
  • 2Shimada K, Sakamoto Y, Sano Y, et al. Reapprasial of the clinical significant of tumor size in patients with pancreatic ductal carcino- ma[ J]. Pancreas,2006,33 (3) :233-239..
  • 3Katz MH, Pisters PW, Evans DB, et al. Border/ine resectable pan- creatic cancer: the importance of this emerging stage of disease [ J ]. J Am Coil Surg,2008,206 (5) :833-846.
  • 4Ishikawa O, Ohigashi H, Yamada T, et al. Radical resection for pancreatic cancer [ J ]. Acta Gastroenterol Belg, 2002, 65 ( 3 ) : 166-170.
  • 5Yeo C J, Cameron JL, Lillemoe KD, et al. Pancreaticoduode-nectomy with or without distal gastrectomy and extended ret-roperitoneal lymphadenectomy for periampullary adenocarcinoma, part 2: ran- domized controlled trial evaluating survival, morbidity, and mortali- ty[ J]. Ann Surg,2002,236 ( 3 ) :355-368.
  • 6Beget HG, Gansauge F, Leder G. Pancreatic cancer: who benefits from curative resection [ J ]. Can J Gastroenterol, 2002, 16 ( 2 ) : 117-120.
  • 7Bilimoria KY, Bentrem D J, Ko CY, et al. Multimodality therapy for pancreatic cancer in the U. S. :utilization,outcomes,and the effect of hospital volume [ J ]. Cancer, 2007,110 ( 6 ) : 1227-1234.
  • 8Di Carlo :, Gianotti L, Balzano G, et al. Complications of pancreat- ic surgery and the role of perioperative nutrition [ J ]. Dig Surg, 1999,16(4) :320-326.
  • 9Halloran CM, Ghaneh P, Bosonnet L, et al. Complications of pan- creatic cancer resection [ J ]. Dig Surg,2002,19 (2) ; 138-146.
  • 10Ellison NM, Chevlen E, Still CD, et al. Support care for patients with pancreatic adenocarcinoma: Symptom control and nutrition [ J ]. Hematol Oncol Clin North Am,2002,16 ( 1 ) : 105-121.

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部